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Abstract The aim of this study was to describe the abnormal-
ities identified with conventional MRI in children with neuro-
psychiatric systemic lupus erythematosus (NPSLE). This was
single-centre (Great Ormond Street Hospital, London) retro-
spective case series of patients with juvenile NPSLE seen in
2003–2013. Brain MR images of the first episode of active
NPSLE were reviewed. All patients fulfilled the 1999 ACR
case definitions for NPSLE syndromes. Presenting neuropsy-
chiatric manifestations, immunological findings and treatment
are reported. Results are expressed as median and ranges or
percentages. Fisher’s exact test was used to identify clinical
predictors of abnormal MRI. A total of 27 patients (22 fe-
males), median age 11 years (4–15), were identified.
Presenting clinical symptoms included the following: head-
aches (85.1 %), mood disorder/depression (62.9 %), seizures
(22.2 %), acute psychosis (18.5 %), cognitive dysfunction
(14.8 %), movement disorder (14.8 %), acute confusional
state (14.8 %), aseptic meningitis (7.4 %), demyelinating syn-
drome (3.7 %), myelopathy (3.7 %), dysautonomia (3.7 %)
and cranial neuropathy (3.7 %). The principal MR findings
were as follows: (1) absence of MRI abnormalities despite
signs and symptoms of active NPSLE (59 %); (2) basilar
artery territory infarction (3 %); (3) focal white matter
hyperintensities on T2-weighted imaging (33 %); (4) cortical
grey matter lesions (3 %); and (5) brain atrophy (18.5 %). The
presence of an anxiety disorder strongly associated with ab-
normal MRI findings (p = 0.008). In over half the children
with NPSLE, no conventional MRI abnormalities were ob-
served; white matter hyperintensities were the most common-
ly described abnormalities. Improved MR techniques coupled
with other alternative diagnostic imaging modalities may im-
prove the detection rate of brain involvement in juvenile
NPSLE.
Keywords Juvenile SLE . Magnetic resonance imaging .
Neuropsychiatric SLE
Introduction
Systemic lupus erythematosus (SLE) is a common autoim-
mune disease that presents before the age of 16 years old in
approximately 10–20 % of cases, and in that context is re-
ferred to as juvenile onset SLE (jSLE) [1]. Neuropsychiatric
SLE (NPSLE) presents with a frequency between 14 and 25%
in children; neuropsychiatric symptoms often develop within
the first year of SLE diagnosis and are related to highmortality
[2–4]. In 1999, the American College of Rheumatology
(ACR) established nomenclature and detailed case definitions
for 14 NPSLE syndromes, which provide a clear description
of the multiple clinical faces of the disorder and standardised
the classification of adults with NPSLE (supplemental
Table 1) [5]. Although paediatric input was minimal, these
definitions are commonly applied to paediatric patients in dai-
ly practice and utilised in clinical research [3, 5]. However,
correct attribution of neuropsychiatric events to NPSLE or to
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an alternative aetiology is a challenge, given the absence of a
diagnostic gold standard for NPSLE.
As magnetic resonance imaging (MRI) is widely available,
it is usually the imaging technique of choice for the work-up
of NPSLE [3, 6]. A wide variety of MRI findings in adults
with NPSLE have been previously described and are sugges-
tive of different NPSLE pathogenetic mechanisms [6, 7]: (1)
focal hyperintensities in white matter or both white and grey
matter, suggestive of vasculitis, or multifactorial autoimmune-
mediated mechanisms of vascular occlusion or narrowing
(vasculopathy with ischaemia); (2) more widespread, conflu-
ent hyperintensities in the white matter, suggestive of chronic
hypoperfusion due to the same mechanisms; (3) diffuse corti-
cal grey matter lesions, compatible with an autoantibody-
mediated immune response to neuronal or other CNS compo-
nents, or postseizure changes; and (4) no conventional MRI
abnormalities at all, despite signs and symptoms of active
disease [6, 7]. However, the role of MRI in the evaluation of
children and adolescents with suspected juvenile NPSLE re-
mains largely unknown.
The aim of this study was therefore to (i) describe the
abnormalities seen on conventional MRI in a large group of
children with jSLE, during episodes of active NPSLE mani-
festations; (ii) identify clinical predictors of abnormalities seen
on conventional MRI.
Patients and methods
PatientsWe retrospectively screened the case notes of a total
of 323 patients with jSLE seen at the paediatric rheumatology
department at Great Ormond Street Hospital for Children
NHS Foundation Trust between April 2003 and October
2013, for patients fulfilling the 1999 ACR case definition for
NPSLE syndromes [8], and in whom at least one MR imaging
study had been performed. All patients met at least 4 of the 11
ACR revised criteria for the classification of SLE [8]. Patients
with neuropsychiatric symptoms that could easily be attribut-
ed to causes other than jSLE were excluded such as patients
with previous existing epilepsy, infection, traumatic brain in-
jury, electrolyte abnormalities, or medication side effects.
Ethical approval was given by the Institute of Child Health/
Great Ormond Street Research Ethics Committee for a retro-
spective case notes review; since this was a retrospective case
note review using de-identified data, written consent from
patients was not required.
The demographic, clinical, and laboratory characteristics
recorded at diagnosis of NPSLE were as follows: sex, age,
ethnicity (established via the information provided by
patients/parents to register with the hospital), previous organ
involvement, manifestations of NPSLE, erythrocyte sedimen-
tation rate (ESR, in the first hour; normal <10 mm/h) and
serum C-reactive protein (CRP; normal range < 10 mg/L),
presence of anti-dsDNA antibodies (normal range 0–20 iu/
ml), antiphospholipid antibodies and lupus anticoagulant,
complement C3 and C4 levels. Therapies used for NPSLE
manifestations were also recorded.
MRI acquisitionMRI and MRAwere performed on a 1.5-T
MR scanner using a standard imaging protocol, including
T2-weighted turbo spin-echo imaging in the axial plane,
fluid-attenuated inversion recovery (FLAIR) sequence in
the coronal plane, T1-weighted spin-echo imaging in the
sagittal plane and three-dimensional short-echo time-of-
flight MRA of the circle of Willis in some patients. When
available, additional sequences such as T1-weighted images
following intravenous gadolinium (Gd) administration,
diffusion-weighted images and apparent diffusion coefficient
maps were also reviewed. An experienced neuroradiologist
(SB) blinded to the clinical status of the patients examined
all images for the presence of any abnormality. Lesions were
categorised as hyperintensities (i.e. showing high signal in-
tensity on T2-weighted images, proton density-weighted im-
ages and/or FLAIR images), parenchymal defects or areas of
focal atrophy (Fig. 1 shows some of the abnormalities).
Parenchymal defects were areas of T2 hyperintensity usually
associated with T1 hypointensity. Atrophy was defined as
areas of brain parenchyma characterised by volume loss be-
tween two scans or as enlarged CSF spaces for a patient of
their given age on a single scan. For each lesion, the behav-
iour following Gd administration were documented.
Depending on their location, lesions were characterised as
cortical grey matter (GM), supratentorial white matter
(WM), basal ganglia, brainstem, spinal cord or cerebellar
WM and GM lesions.
Statistical analysis
Descriptive statistics were used to describe the study cohort:
continuous variables were summarised as median and range;
categorical variables were presented as percentages.
Parameters between groups were compared using the
Fisher’s exact test. A two-sided p value <0.05 was considered
statistically significant. Statistical analysis was done with IBM
SPSS statistics version 21.
Results
Demographics, jSLE and NPSLE features
A total of 27 patients (22 females) of median age of 11 years
(range 4–15) with NPSLE were included in the study. Eleven
out of 27 (40.7 %) were Afro-Caribbean; 4/27 (14.8 %) were
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Pakistani; 7/27 (25.9 %) were Caucasian; and the remaining
4/27 (14.8 %) were of mixed ethnic background.
The median age of jSLE disease onset was 11 years old
(range 4–15), and the median time from diagnosis to the de-
velopment of NPSLE symptoms was 16months (range 0–70).
The jSLE disease features from diagnosis to the time patients
developed suspected NPSLE are summarised in Table 1.
Persistent severe headaches were the most frequent neuro-
psychiatric manifestation, occurring in 23/27 (85.1 %) pa-
tients, followed by mood disorder/depression in 17/27
(62.9 %); anxiety disorder in 7/27 (25.9 %); seizures in 6/27
(22.2%); acute psychosis in 5/27 (18.5 %); cognitive dysfunc-
tion in 4/27 (14.8 %); movement disorder in 4/27 (14.8 %);
acute confusional state in 4/27 (14.8 %); aseptic meningitis in
2/27 (7.4 %); demyelinating syndrome 1/27 (3.7 %); myelop-
athy 1/27 (3.7 %); dysautonomia 1/27 (3.7 %); and cranial
neuropathy in another patient (3.7 %).
Laboratory and other investigations
Antinuclear antibodies were positive in all 27 patients, and
anti-dsDNA antibodies were present in 20/27 (74 %) of pa-
tients, at a median level of 14 iu/ml (range 0.5–400). Low C3
levels were documented in 14/27 (51.8 %) patients and low
C4 in 15/27 (55.5 %). ENA antibodies were detected in 14/27
patients (51.8 %): anti-Ro antibodies in 8 patients; anti-La in 2
patients (both positive for anti-Ro as well); 6 patients were
positive for anti-RNP, and 2 of these were also positive for
anti-SM antibodies. IgG anticardiolipin antibodies (ACL)
were positive in 10 out of 27 (37 %) patients at the time of
acute NPSLE; lupus anticoagulant was positive in 4/27 (14%;
all positive for IgG ACL as well); and anti-β2 glycoprotein
antibodies were positive in 1/11 patients tested (positive for
lupus anticoagulant too). Median ESR was 24 mm/h (range
10–75); median CRP 25 mg/L (5–45).
CSF examination was performed in two patients: this dem-
onstrated pleocytosis in both cases (mainly lymphocytes),
with CSF normal protein and glucose levels, and negative
CSF culture in both cases.
Electroencephalography (EEG) was performed in 11/27
(40 %) patients; a total of 5/11 of these cases had presented
with seizures. EEG was abnormal in 2/11 patients tested, with
EEG showing generalised spike waves.
MRI abnormalities and NPSLE presentation
A total of 27 imaging studies were reviewed; gadolinium
contrast-enhanced images were available in 23/27cases.
Diffusion-weighted images were available for 21/27 MRI
scans.
Sixteen of 27 (59.3 %) patients spanning eight different
ACR NPSLEmanifestation categories had noMRI abnormal-
ity demonstrated in both precontrast and postcontrast images
(available in all 16 cases). Their NPSLE syndromes were
Fig. 1 a Representative example of a grey matter signal hyperintensity
(arrow) seen on the coronal FLAIR image (long arrow). b Clusters of T2
hyperintensities (arrows) in the frontal white matter seen on T2-weighted
images. Note the background of sulcal and ventricular enlargement
possibly resulting from cerebral atrophy. c Sagittal T2 hyperintensity of
the cord (arrows) that resolved and remitted over a number of years.
FLAIR fluid-attenuated inversion recovery
Table 1 Summary of juvenile onset systemic lupus erythematosus
(jSLE) disease features from diagnosis to the time patients developed
neuropsychiatric syndromes. Definitions are based on the revised
American College of Rheumatology (ACR) criteria for classification of
SLE [8]
Clinical manifestations N of 27 patients (% of total)
Malar rash 21 (77 %)
Discoid lupus 10 (37 %)
Photosensitivity 11 (40 %)
Oral or nasal ulceration 10 (37 %)
Arthritis 17 (62 %)
Serositis 14 (51 %)
Nephritis 18 (66 %)
Neurological disease 27 (100 %)
Haematological disorder 19 (70 %)
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seizures (n = 2), cerebrovascular disease (n = 1), headaches
(n = 14), movement disorder (n = 1), cognitive disorders
(n = 2), psychiatric disorders (n = 11), and cranial neuropathy
(n = 1). Three of these 16 patients also had cerebral MRA; this
was normal in all cases. Ten of 16 patients also had diffusion-
weighted imaging scans; normal diffusion was noted in all.
MRI scans were abnormal in the remaining 11 patients
presenting with seizures (n = 4), aseptic meningitis (n = 2),
cerebrovascular disease (n = 2), demyelination (n = 1), head-
aches (n = 9), movement disorder (n = 3), transverse myelop-
athy (n = 1), cognitive disorders (n = 3), psychiatric disorders
(n = 8), autonomic disorder (n = 1), peripheral neuropathy
(n = 1), and myasthenia-like syndrome (n = 1). No patients
in our cohort had sensorineural hearing loss. The most fre-
quent radiographic finding in our 11 patients with abnormal
scans was hyperintensity on T2 in 9/11 (81.8 %). One or more
white matter hyperintensities were observed in 8/11 (72.2 %)
of NPSLE patients with other MRI abnormalities occurring in
various numbers and sizes. One child had an acute basilar
artery occlusion resulting in infarction of the cerebellum,
brainstem, posterior thalamus on the right and mild hydro-
cephalus with restricted diffusion (Fig. 2). Of the remaining,
white matter hyperintensity lesions occurred in the
supratentorial white matter in 7/8 patients (88.9 %), in the
brainstem in one patient (11.1 %). Multiple white matter le-
sions these were distributed asymmetrically. White matter le-
sions were present in patients with all types of ACR-defined
NPSLE syndromes in this study (Table 2).
Greymatter hyperintensities were observed in 1/11 patients
affecting the cortex (Fig. 1). This patient also showed multi-
ple, similar-appearing, focal white matter lesions. There was
also restricted diffusion in the scan.
One or more parenchymal defects were detected in a single
patient; lesions were located in the cerebellum and were in the
presence of other white matter or grey matter lesions.
One child had T2 hyperintensities in the cervicothoracic
cord that came and went over a number of years and was
diagnosed as having a transverse myelitis (Fig. 1c).
Another child had an extensive acute infarction of the mid-
brain and both cerebellar hemispheres with ischaemic change
in the deep white matter watershed regions of both cerebral
hemispheres, body of the corpus callosum and left parietal
cortex (Fig. 2). MRA revealed occlusion of the distal basilar
artery.
Cerebral atrophy was diagnosed in five patients; this was
located in the supratentorial white matter in 4/5 patients and in
the cortical grey matter in one patient.
Regarding post-Gd administration images, there was
no contrast enhancement in 19/24 scans including no
enhancement of the infarcted area for the patient with
the basilar artery infarction. There was patchy enhance-
ment over the spinal lesions for the patient with trans-
verse myelitis; parotid gland enhancement for one patient
with no intracerebral lesion enhancement; and enhance-
ment over a small incidental developmental venous
anomaly for another patient.
Fig. 2 Infarction in a 14 year old
with NPSLE of the a cerebellum,
b brainstem, and c right posterior
thalamus (arrow) diagnosed on
the T2-weighted MR images.
Cerebellar swelling compressing
the fourth ventricle resulted in
mild hydrocephalus. d The
diffusion-weighted imaging
revealed a high signal lesion in
keeping with an acute infarct. e A
signal void of the distal basilar
artery (white arrow) on the MRA
of the posterior circulation
revealed a large vessel occlusion.
fMultiple borderzone infarcts are
seen within the deep white matter
of the frontal lobes, some of
which were acute. The anterior
circulation was normal (not
shown)
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Clinical predictors of abnormal brain MRI
There was a significant association between the presence
of an anxiety disorder and abnormal brain MRI scans
(p = 0.008). There was no specific association between
other NPSLE manifestations, disease duration, presence
of ACL and presence of cerebral abnormalities on MRI
(Table 3).
Treatment
The treatment received by the 27 patients for the suspected
NPSLE included: intravenous corticosteroids (30 mg/kg/day
for 3 days followed by 2 mg/kg of oral prednisolone tapered
over 3–6 months) in all patients; intravenous cyclophospha-
mide (500 mg–750 mg/m2 monthly over 6 months) in 14/27
(51.8 %) patients; rituximab (750 mg/m2 two doses repeated
in 2 weeks) in 11/27 (40.7 %) patients; and plasma exchange
(two volume exchanges per day over 5 cycles) in 3/27
(11.1 %) patients. Four of 27 (14.8 %) patients received
aspirin as an antiplatelet agent; 6/27 patients (22.2 %)
received anticoagulation therapy (warfarin or low-
molecular-weight heparin); all these patients were positive
for IgG ACL. A total of 4 of the 6 patients with seizures
received antiepileptic medication that was discontinued after
12–18 months.
Discussion
In this observational study, we describe the cerebral abnormal-
ities detected using MRI during active NPSLE episodes in
jSLE. Surprisingly, brain MRI was normal in 59 % of our
patients, an observation we suggest is clinically important
since it emphasises that a normal brain MRI does not exclude
potentially reversible NPSLE. Presentation with an anxiety
disorder strongly associated with the presence of an abnormal
MRI, despite patients not presenting with any focal neurolog-
ical manifestations. This finding is also of considerable clini-
cal relevance since physicians may dismiss anxiety in this
context as being a feature of chronic illness and its treatment,
rather than due to potentially reversible organic brain disease
per se.
The 59 % of patients with normal MRI scans exhibited a
wide variety of NPSLE symptoms. This is in line with previ-
ous studies in adults with NPSLE that demonstrated up to
42 % of patients with active NPSLE had a normal MRI [7].
This observation highlights the limitations of conventional
MR scanning used in routine clinical care to detect brain ab-
normalities, despite strong clinical suspicion of NPSLE.
Better neuroimaging techniques for NPSLE that are capable
of identifying the underlying pathological mechanism
(inflammatory and thrombotic) are needed to facilitate the
diagnosis of NPSLE, particularly since treatment delay can
be associated with high morbidity and mortality. Novel
Table 3 Predictors of abnormal brain magnetic resonance imaging
(MRI) in patients with neuropsychiatric syndromes associated
with systemic lupus erythematosus (NPSLE). Groups were com-
pared using Fisher’s exact test; p < 0.05 was considered significant.
ACL anticardiolipin antibodies
Presence of NPSLE syndrome Normal MRI Abnormal MRI p value
Seizure disorder
Yes 2 4 0.187
No 14 7
Aseptic meningitis
Yes 0 2 0.156
No 16 9
Cerebrovascular disease
Yes 1 2 0.548
No 15 9
Demyelinating syndrome
Yes 0 1 0.4
No 16 10
Headache
Yes 14 9 1
No 2 2
Movement disorder
Yes 1 3 0.27
No 15 8
Transverse myelopathy
Yes 0 1 0.4
No 16 10
Cognitive disorders
Acute confusional state
Yes 1 3 0.27
No 15 8
Cognitive dysfunction
Yes 1 3 0.27
No 15 8
Psychiatric disorders
Anxiety disorder
Yes 1 6 0.008
No 15 5
Mood disorder / depression
Yes 9 8 0.44
No 7 3
Psychosis
Yes 1 4 0.125
No 15 7
Autonomic disorder
Yes 0 1 0.4
No 16 10
Peripheral neuropathy
Yes 0 1 0.4
No 16 10
Cranial neuropathy
Yes 1 0 1
No 15 11
Myasthenia-like syndrome
Yes 0 1 1
No 16 10
Disease duration
<12 months 9 6 1
>12 months 7 5
Presence of ACL
Yes 7 3 0.44
No 9 8
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functional and quantitative MRI techniques such as magnetic
resonance spectroscopy (MRS), magnetisation transfer imag-
ing (MTI), diffusion-weighted imaging (DWI), and perfusion-
weighted imaging (PWI), as well as nuclear imaging tech-
niques, such as single-photon emission computed tomography
(SPECT) may have a role in detecting changes in juvenile
NPSLE, and could facilitate earlier diagnosis [9–12].
QuantitativeMRI techniques are also now beginning to reveal
abnormalities in NPSLE patients with normal conventional
MRI scans [10]. The clinical relevance of these approaches
therefore requires further validation in jSLE.
Our observations in jSLE concur with those of previous
studies in adults showing that white matter hyperintensities
were the most commonly observed lesion in patients with an
abnormal MRI scan [6, 7]. Notably, white matter lesions have
also been shown to be present in some patients without
NPSLE, suggesting that these lesions are common and their
specificity remains to be established [6]. In addition, and whilst
the exact pathophysiology of these NPSLE-related focal white
matter hyperintensities remains unclear, previous reports dem-
onstrated a strong correlation between the presence of these
lesions and scores of NPSLE disease activity, emphasising their
clinical relevance and suggesting an aetiological link [13, 14].
We did not have many patients with infarcts due to throm-
boembolic occlusion of any medium or large arteries (n = 1),
in contrast to studies in adults with NPSLE [6]. Additional
factors such as higher incidence of antiphospholipid syndrome
in adults, and/or accelerated atherosclerosis may explain this
observed difference.
Our study is limited by all the usual caveats around small,
largely descriptive retrospective case studies, an unavoidable
situation since NPSLE is so rare in the young. We used
standardised protocols for conventional MRI sequences (such
as T1-weighted [with and without contrast agents], T2-
weighted, and FLAIR images), as utilised for routine care in
our institution for at least 10 years. Further characterisation of
the lesions with more recently introduced techniques such as
diffusion-weighted imaging was performed for the majority of
the patients but not for all cases and may have increased the
MRI detection yield. We have also not tested for the presence
of recently described antineuronal antibodies that have been
demonstrated in some patients with jSLE [15], since these
tests were not routinely available at our institution.
In summary, normal conventional MRI scans were ob-
served in 59 % of our patients with clinically active NPSLE.
Therefore, a normal conventional MRI study cannot reliably
exclude a diagnosis of NPSLE. For the remaining 41 %, we
observed several distinct radiographic patterns likely reflec-
tive of different NPSLE pathogenic mechanisms. Anxiety dis-
order strongly associated with the presence of an abnormal
MRI. Improved neuroimaging techniques that combine mor-
phological with functional imaging may in the future improve
the detection rate of brain involvement in juvenile NPSLE.
Compliance with ethical standards Ethical approval was given by the
Institute of Child Health/Great Ormond Street Research Ethics
Committee for a retrospective case notes review; since this was a retro-
spective case note review using de-identified data, written consent from
patients was not required.
Disclosure None.
Financial support No financial support for the work reported in this
article.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted
use, distribution, and reproduction in any medium, provided you
give appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes weremade.
References
1. Watson L, LeoneV, Pilkington C, Tullus K, Rangaraj S,McDonagh
JE, et al. (2012) Disease activity, severity, and damage in the UK
juvenile-onset systemic lupus erythematosus cohort. Arthritis &
Rheumatism 64:2356–2365
2. Harel L, Sandborg C, Lee T, von Scheven E (2006) Neuropsychiatric
manifestations in pediatric systemic lupus erythematosus and associ-
ation with antiphospholipid antibodies. J Rheumatol 33:1873–1877
3. Benseler SM, Silverman ED (2007) Review: Neuropsychiatric in-
volvement in pediatric systemic lupus erythematosus. Lupus 16:
564–571
4. Sibbitt WL, Brandt JR, Johnson C, MaldonadoME, Patel SR, Ford
CC, et al. (2002) The incidence and prevalence of neuropsychiatric
syndromes in pediatric onset systemic lupus erythematosus. J
Rheumatol 29:1536–1542
5. Liang MH, Corzillius M, Bae SC, Lew RA, Fortin PR, Gordon C,
et al. (1999) The American College of Rheumatology nomenclature
and case definitions for neuropsychiatric lupus syndromes. Arthritis
Rheum 42:599–608
6. Ainiala H, Dastidar P, Loukkola J, Lehtimñki T, Korpela M, Peltola
J, et al. (2005) Cerebral MRI abnormalities and their association
with neuropsychiatric manifestations in SLE: a population-based
study. Scand J Rheumatol 34:376–382
7. Luyendijk J, Steens SCA, Ouwendijk WJN, Steup-Beekman GM,
Bollen ELEM, van der Grond J, et al. (2011) Neuropsychiatric
systemic lupus erythematosus: lessons learned from magnetic res-
onance imaging. Arthritis & Rheumatism 63:722–732
8. Hochberg MC (1997) for the Diagnostic and Therapeutic Criteria
Committee of the American College of Rheumatology. Updating
the American College of Rheumatology revised criteria for the clas-
sification of systemic lupus erythematosus. Arthritis Rheum 40:1725
9. Ercan E, Ingo C, Tritanon O, Magro-Checa C, Smith A, Smith S,
et al. (2015) A multimodal MRI approach to identify and charac-
terize microstructural brain changes in neuropsychiatric systemic
lupus erythematosus. NeuroImage, Clinical
10. Appenzeller S, Vasconcelos Faria A, Li LM, Costallat LT, Cendes F
(2008) Quantitative magnetic resonance imaging analyses and clin-
ical significance of hyperintense white matter lesions in systemic
lupus erythematosus patients. Ann Neurol 64:635–643
11. Welsh RC, Rahbar H, Foerster B, ThurnherM, Sundgren PC (2007)
Brain diffusivity in patients with neuropsychiatric systemic lupus
erythematosus with new acute neurological symptoms. J Magn
Reson Imaging 26:541–551
Clin Rheumatol (2016) 35:2449–2456 2455
12. Appenzeller S, Costallat LT, Li LM, Cendes F (2006) Magnetic
resonance spectroscopy in the evaluation of central nervous system
manifestations of systemic lupus erythematosus. Arthritis Care &
Research 55(5):807–811
13. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH,
Austin A, et al. (1992) Derivation of the SLEDAI. A disease activ-
ity index for lupus patients. Arthritis & Rheumatism 35:630–640
14. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Sanchez-
Guerrero J, et al. (1996) The development and initial validation of
the Systemic Lupus International Collaborating Clinics/
American College of Rheumatology damage index for sys-
temic lupus erythematosus. Arthritis & Rheumatism 39:363–
369
15. Fragoso-Loyo H, Cabiedes J, Orozco-Narvíez A, Dávila-
Maldonado L, Atisha-Fregoso Y, Diamond B, et al. (2008) Serum
and cerebrospinal fluid autoantibodies in patients with neuropsy-
chiatric lupus erythematosus Implications for diagnosis and patho-
genesis. PloS One 3:e3347
2456 Clin Rheumatol (2016) 35:2449–2456
